companiesandmarkets.com

Return to Report | Print

Labopharm Inc - Premium Company Profile

http://www.companiesandmarkets.com/Summary-Company-Profile/labopharm-inc-premium-company-profile-41341.asp

Report Summary

Introduction

Labopharm, formerly known as Centre de Recherche Appliquee Pharmaceutique (CRAP), is a specialty pharmaceutical company optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies: Contramid and PNDS. . It is currently focusing on developing and commercializing its lead product candidate, Trazodone for the potential treatment of depression.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    Labopharm's primary focus is developing small molecule drugs for two therapeutic indications, pain and depression. The company currently has one marketed product, Tramadol, indicated for moderate to severe pain, in Europe and Canada through its marketing partners. Trazodone, indicated for depression is currently in Phase III clinical development.

    The company's total revenues increased at a CAGR of 102.9% during 2002-2006, from $0.8 million to $14 million. This represents an absolute total growth of +$13.1 million for total revenues during the same period. License, collaboration and other revenues are a major contributor to revenue growth by contributing +$7.1 million.

    The company's biggest contributor to sales growth out to 2010 again will be revenues from license, collaboration and other. Revenues from license, collaboration and other are expected to increase from $8 million in 2006 to $75 million in 2010, recording an absolute growth of +$67 million.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    TABLE OF CONTENTS
    Overview 1
    Catalyst 1
    Summary 1
    Company Structure 6
    Company Overview and Key Facts 6
    Business Description 7
    History 9
    Locations and Subsidiaries 12
    Company Financials 13
    Stock Market Performance 13
    P&L 15
    Balance Sheet 18
    Cash Flow 18
    Business Segment Performance 19
    Geographic Segment Performance 21
    Products & Services 22
    Marketed Products 22
    Pipeline Products 23
    Historical Product Sales 25
    AC Forecast Product Sales 26
    Competitors and Strategic Business Relationships 28
    Key Competitors 28
    Key Suppliers 28
    Key Clients 29
    Shareholding Structure 30
    Strategy 31
    Company View 31
    Corporate Strategy 34
    SWOT Analysis 36
    Overview 36
    Strengths 37
    Weaknesses 38
    Opportunities 39
    Threats 40
    Value Chain Analysis 42
    Overview 42
    Discovery and Product Development 43
    Sales 43
    Scorecard 44
    Overview 44
    Scorecard Analysis 45
    Key Employees 46
    List of Key Employees 46
    Key Employee Biographies 47
    Financial and Operational Overview 52
    Financial and Operational Overview 52
    APPENDIX 55
    Ask the analyst 55
    Datamonitor consulting 55
    Disclaimer 55


    TABLE OF FIGURES
    Figure 1: Labopharm - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 16
    Figure 2: Labopharm - Key Strategic Revenues, 2002-2006 ($ Mn) 20
    Figure 3: Labopharm - Key Strategic Revenues, 2006-2010 ($ Mn) 27


    TABLE OF TABLES
    Table 1: Labopharm - Key Facts 6
    Table 2: Labopharm – Locations and Subsidiaries 12
    Table 3: Labopharm - Year-End Share Price and Market Capitalization, 2002-2006 ($) 13
    Table 4: Labopharm - Key Events Impacting Share Price Performance 14
    Table 5: Labopharm - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 15
    Table 6: Labopharm - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 17
    Table 7: Labopharm - Balance Sheet, 2002-2006 ($ Mn) 18
    Table 8: Labopharm – Cash Flow, 2002-2006 ($ Mn) 18
    Table 9: Labopharm - Revenue Breakdown by Division, 2002-2006 ($ Mn) 19
    Table 10: Labopharm - Geographic Breakdown, 2002-2006 ($ Mn) 21
    Table 11: Labopharm - Marketed Products 22
    Table 12: Labopharm - In-house Pipeline Products 23
    Table 13: Labopharm - Collaboration Products 24
    Table 14: Labopharm – Product Sales, 2002-2006 ($ Mn) 25
    Table 15: Labopharm - Forecast Sales, 2006-2010 ($ Mn) 26
    Table 16: Labopharm - Key Competitors 28
    Table 17: Labopharm - Key Suppliers 28
    Table 18: Labopharm - Key Clients 29
    Table 19: Labopharm - Key Shareholders 30
    Table 20: Labopharm - SWOT Analysis Summary 36
    Table 21: Labopharm - Value Chain Analysis 42
    Table 22: Labopharm - Scorecard 44
    Table 23: Labopharm - Key Employees 46
    Table 24: Labopharm - Financial and Operational Overview 53